Tumors formed from HCC827 and PC9 NSCLC cells, which harbor activated EGFR signaling resulting from mutations in exon 21 and exon 19, respectively, were sensitive to HM90822B treatment and shrank by approximately eight-fold compared with tumors in mice treated with PBS. Here, EGFR is linked to non-small cell lung carcinoma.